PRZOOM - /newswire/ -
Raleigh, NC, United States, 2012/02/21 - Dr. Marian Meyer manages the company’s chemistry and microbiology labs, which are responsible for such quality-control services as materials testing and release, environmental monitoring and analytical methods compliance - OsoBio.com.
Dr. Marian Meyer has been named director of laboratories at OSO BioPharmaceuticals Manufacturing, LLC.
In her role, Meyer manages the company’s chemistry and microbiology labs, which are responsible for such quality-control services as materials testing and release, environmental monitoring and analytical methods compliance.
Meyer brings to OsoBio more than 15 years of pharmaceutical industry experience in sterile injectables manufacturing, contract steriles, biologics, and tablets and capsules manufacturing. Most recently, she served as quality control manager for raw materials, microbiological, stability and compliance for Sandoz in Broomfield, Colo.
Meyer is a member of the Small Molecules 4 expert committee for United States Pharmacopeia (USP), a non-governmental, official public standards-setting authority for prescription and over-the-counter medicines and other health-care products manufactured or sold in the United States. USP standards for quality, purity, strength and consistency are recognized and used in more than 130 countries.
Having received her doctorate in chemistry from Arizona State University, Meyer also holds a master’s degree in business administration from Loyola University.
OSO BioPharmaceuticals Manufacturing, LLC (OsoBio.com), is a contract manufacturing organization (CMO) focusing on biologic and pharmaceutical injectables.
Headquartered in Albuquerque, N.M., OsoBio specializes in products requiring complex handling, including highly potent compounds. Responsiveness, attention to detail and clear communication are the hallmarks of our client care.
OsoBio surpasses quality-assurance expectations within our industry. Our employees are industry veterans who provide innovative solutions to our clients’ most difficult projects.